Sensei Biotherapeutics, Inc. (NASDAQ:SNSE) Receives Average Rating of “Hold” from Analysts

Shares of Sensei Biotherapeutics, Inc. (NASDAQ:SNSE) have been given a consensus recommendation of “Hold” by the seven analysts that are covering the company, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation, two have given a hold recommendation and four have assigned a buy recommendation to the company. The average 1-year target price among brokerages that have updated their coverage on the stock in the last year is $48.00.

Several analysts recently commented on SNSE shares. Wall Street Zen downgraded shares of Sensei Biotherapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, May 16th. Citigroup started coverage on shares of Sensei Biotherapeutics in a research report on Friday, May 22nd. They issued a “buy” rating and a $55.00 price target for the company. BTIG Research initiated coverage on shares of Sensei Biotherapeutics in a research report on Thursday, June 11th. They issued a “buy” rating and a $55.00 price target for the company. Weiss Ratings restated a “sell (d-)” rating on shares of Sensei Biotherapeutics in a research report on Friday, April 24th. Finally, Loop Capital set a $50.00 price objective on shares of Sensei Biotherapeutics in a research report on Thursday, May 28th.

Sensei Biotherapeutics Price Performance

SNSE stock opened at $13.85 on Tuesday. The company has a fifty day moving average price of $22.94 and a 200 day moving average price of $18.96. Sensei Biotherapeutics has a 12 month low of $5.86 and a 12 month high of $36.76. The company has a market cap of $18.56 million, a price-to-earnings ratio of -0.10 and a beta of -0.25.

Sensei Biotherapeutics (NASDAQ:SNSE) last released its quarterly earnings results on Friday, May 15th. The company reported ($131.45) EPS for the quarter, missing the consensus estimate of ($0.62) by ($130.83).

Insiders Place Their Bets

In other news, major shareholder Millennium Management Llc acquired 15,321 shares of the business’s stock in a transaction on Friday, March 27th. The stock was bought at an average price of $26.61 per share, for a total transaction of $407,691.81. Following the transaction, the insider owned 142,360 shares in the company, valued at $3,788,199.60. This represents a 12.06% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, major shareholder James Peyer sold 25,000 shares of the company’s stock in a transaction on Monday, June 1st. The stock was sold at an average price of $20.02, for a total transaction of $500,500.00. Following the transaction, the insider owned 130,142 shares of the company’s stock, valued at approximately $2,605,442.84. The trade was a 16.11% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders have acquired 46,980 shares of company stock valued at $1,341,669 and have sold 48,067 shares valued at $1,204,939. 7.00% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Sensei Biotherapeutics

A number of large investors have recently bought and sold shares of the company. Vivo Capital LLC purchased a new position in Sensei Biotherapeutics during the 1st quarter worth $22,758,000. Stempoint Capital LP purchased a new position in shares of Sensei Biotherapeutics in the 1st quarter valued at about $4,188,000. Bank of America Corp DE increased its holdings in shares of Sensei Biotherapeutics by 10,692.5% in the 1st quarter. Bank of America Corp DE now owns 33,025 shares of the company’s stock valued at $1,041,000 after purchasing an additional 32,719 shares in the last quarter. Finally, Renaissance Technologies LLC increased its holdings in shares of Sensei Biotherapeutics by 178.2% in the 1st quarter. Renaissance Technologies LLC now owns 32,041 shares of the company’s stock valued at $1,010,000 after purchasing an additional 20,525 shares in the last quarter. Hedge funds and other institutional investors own 10.50% of the company’s stock.

About Sensei Biotherapeutics

Sensei Biotherapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of immunotherapies that harness both the innate and adaptive arms of the immune system to treat cancer and autoimmune diseases. Utilizing proprietary antibody engineering and biologics platforms, Sensei aims to develop next-generation checkpoint modulators and immune agonists designed to overcome the limitations of current therapies.

The company’s lead programs include SIS-100, a first-in-class antagonist targeting Siglec-15 being evaluated in solid tumors to relieve immune suppression in the tumor microenvironment, and SIS-101, an antibody directed against CD39 intended to restore T-cell function by modulating adenosine signaling pathways.